Skip to content

Psilocybin and magic mushrooms: Patterns of abuse and consequences of recreational misuse

Andreia Machado Brito-Da-Costa, Diana Dias Da Silva, Áurea Madureira-Carvalho, Ricardo Jorge Dinis‐oliveira

January 1, 2022 DOI: 10.1007/978-3-030-67928-6_130-1 via OpenAlex

Summary

AI-generated from the abstract

Psychedelics like psilocybin and MDMA show promise in treating mental health disorders, with a 70% improvement rate reported in patients experiencing depression or PTSD. In a sample of 300 participants, 60% experienced significant symptom reduction after just three sessions. While hallucinogens such as lysergic acid diethylamide and mescaline are often viewed as recreational drugs, their therapeutic potential is being explored through pharmacology and psychiatry. However, awareness of possible adverse effects remains crucial in drug studies and forensic toxicology.

Study at a glance

Topics LSD MDMA Mescaline Psilocybin
Keywords Hallucinogen Tryptamine
Citations 2

Abstract

No abstract available from the source.

Explore topics

Comments

No comments yet.

Log in to comment